Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory Multiple Myeloma(MM)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Study completedNCT03269136
What this trial is testing

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Pfizer 101
Early research (Phase 1)Ended earlyNCT02579824
What this trial is testing

Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Myeloma
M.D. Anderson Cancer Center 14
Testing effectiveness (Phase 2)Study completedNCT03242460
What this trial is testing

The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed and/or refractorY Multiple Myeloma
Kosin University Gospel Hospital 55
Testing effectiveness (Phase 2)Looking for participantsNCT07637578
What this trial is testing

Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in Relapse+1 more
SCRI Development Innovations, LLC 46
Testing effectiveness (Phase 2)UnknownNCT05739188
What this trial is testing

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 18
Early research (Phase 1)Looking for participantsNCT04771572
What this trial is testing

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Who this might be right for
Non Hodgkin LymphomaRichter TransformationMultiple Myeloma+10 more
Newave Pharmaceutical Inc 100
Very early researchNot Yet RecruitingNCT07399444
What this trial is testing

A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma（LB2505-0001）

Who this might be right for
Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China 38
Very early researchActive Not RecruitingNCT05302648
What this trial is testing

To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM

Who this might be right for
Multiple Myeloma
Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT01166113
What this trial is testing

Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma (MM) Relapsed and/or Refractory to Lenalidomide

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 67
Early research (Phase 1)Looking for participantsNCT05927571
What this trial is testing

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Genentech, Inc. 120
Early research (Phase 1)Study completedNCT03106428
What this trial is testing

A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies

Who this might be right for
Acute Myeloid LeukemiaMultiple MyelomaDiffuse Large B-cell Lymphoma
MedImmune LLC 67
Early research (Phase 1)Looking for participantsNCT07280013
What this trial is testing

Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Who this might be right for
Multiple Myeloma (MM)
C4 Therapeutics, Inc. 60
Very early researchUnknownNCT04412889
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Who this might be right for
Multiple Myeloma
Hebei Yanda Ludaopei Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06292780
What this trial is testing

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Who this might be right for
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals 220
Not applicableLooking for participantsNCT06961669
What this trial is testing

Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell Lymphoma

Who this might be right for
Lymphoblastic LeukemiaRelapsed or Refractory Multiple Myeloma (RRMM)
Anhui Provincial Hospital 18
Testing effectiveness (Phase 2)Looking for participantsNCT06832865
What this trial is testing

ELISA in Relapsed/Refractory MM

Who this might be right for
Relapsed Refractory Multiple Myeloma (RRMM)Relapsed Refractory Multiple Myeloma
Massachusetts General Hospital 30
Early research (Phase 1)Ended earlyNCT04702425
What this trial is testing

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Who this might be right for
Non-Hodgkin Lymphoma (NHL)Acute Myeloid Leukemia (AML)Multiple Myeloma (MM)
Novartis Pharmaceuticals 37
Not applicableLooking for participantsNCT07051850
What this trial is testing

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Who this might be right for
Multiple Myeloma, RelapsedMultiple Myeloma (MM)
Sung-Soo Park 174
Large-scale testing (Phase 3)Active Not RecruitingNCT04975997
What this trial is testing

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
Celgene 939
Not applicableNot Yet RecruitingNCT07015021
What this trial is testing

The Efficacy and Safety of the Combination Therapy of Daratumumab, Cabozantinib, Pomalidomide, and Dexamethasone (D-KPd) in the Treatment of High-risk First-time Relapsed or Primary Refractory MM Patients

Who this might be right for
Multiple MyelomaCarfilzomibDaratumumab+1 more
The First Affiliated Hospital of Soochow University 72
Next Page